Skip to content

Phase 3 Study of KW-6002 (6002-009)

Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 in the Treatment of Parkinson's Disease (Phase 3)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220820
Enrollment
360
Registered
2009-08-18
Start date
2009-08-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Be willing and able to give written informed consent 2. UK Parkinson's Disease Society brain bank criteria (Step 1 and 2) for PD 3. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale 4. On levodopa/dopa-decarboxylase inhibitor for at least one year 5. Taking at least three doses and >=300 mg of levodopa/dopa-decarboxylase inhibitor per day 6. Predictable end of dose wearing off 7. Able to satisfactorily complete Hauser based 24-hour patient Parkinson's diary 8. Have an average of two hours of OFF time on 24-hour patient Parkinson's diaries 9. On a stable regimen of any other anti-Parkinson's drugs 10. On a stable dose of domperidone

Exclusion criteria

Exclusion criteria: 1. Taking any excluded medications 2. Neurosurgical treatment or Transcranial Magnetic Stimulation for PD 3. Diagnosis of cancer 4. Diagnosis of clinically significant illness of any organ system 5. Diagnosis of dementia or Mini-Mental Status Examination score of 23 or less 6. History of drug or alcohol abuse or dependence 7. History of psychosis 8. History of significant drug allergies 9. Taking anticonvulsants for seizures 10. History of neurological malignant syndrome 11. Pregnant or lactating females

Design outcomes

Primary

MeasureTime frame
Efficacy: 24-hour patient Parkinson's diaries

Secondary

MeasureTime frame
Safety: adverse events

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026